Transcript: Wednesday, July 2, 2014

NBR ThumANNOUNCER: This is NIGHTLY BUSINESS REPORT with Tyler Mathisen and Susie Gharib.

BILL GRIFFETH, NIGHTLY BUSINESS REPORT ANCHOR: Hiring spree? Private businesses add more jobs than expected last month, increasing optimism
about tomorrow`s employment report.

Strategies investors can use to find value in this record-setting market.

GRIFFETH: Side effects. Are discount prescription drugs not purchased at pharmacies safe? The results of a six-month investigation.

We have all that and more tonight on NIGHTLY BUSINESS REPORT for this
Wednesday, July 2nd.

Good evening, everybody. I`m Bill Griffeth, in for Tyler Mathisen

GHARIB: And I`m Susie Gharib. Good evening from me, as well.

Well, more Americans are back on the job at the office, at school, at the mall and at construction sites all across the country, and that`s raising expectations for a strong June jobs report from the Labor Department tomorrow.

Now, payroll firm ADP reported today that private sector employers added many more new workers than expected and the most new jobs added in one month since November of 2012. Gains were seen in every sector of the labor market with small firms, those with fewer than 20 employees hiring the most.

Hampton Pearson has more on today`s encouraging numbers and what to
expect in tomorrow`s report.


One day ahead of the June job`s report, optimism is at a four-year high.
The consensus forecast sees the economy adding 215,000 jobs last month, boosted by today`s headline. The private sector may have added 281,000
jobs. That`s according to payroll processer ADP.

MARK ZANDI, MOODY`S ANALYTICS CHIEF: It was everywhere. The gains were broad based. Every single industry added to payrolls every company size added to payrolls. It was uniformly strong and, you know, just
looking at the underlying ADP data, it looks really, really good.

PEARSON: Market watchers hope job great can sustain. The labor market has added more than 200,000 jobs in each of the last four months, the best performance since the 1990s. It`s a contrast of disappointing economic data showing a nearly 3 percent GDP contraction in the first
quarter and less than expected consumer spending in May.

STEVE RICCHIUTO, MIZUHO CHIEF U.S. ECONOMIST: But the one wild card has always been the consumer. Nothing is really sustainable in terms of all the other components of GDP unless you have the backdrop of consumer spending, which means not only do you need employment, but you need income
being generated out of that employment.

PEARSON: No hint from Federal Reserve Chair Janet Yellen today about how another strong jobs report might impact the Fed timetable for raising interest rates. Yellen telling an International Monetary Fund conference a big part of the Fed`s communication strategy is to avoid surprising
financial markets.

JANET YELLEN, FEDERAL RESERVE CHAIR: We will try to conduct monetary policy to communicate about it and to conduct it in the manner that is understandable to financial markets, to avoid the kinds of surprises that
could cause jumps in interest rates.

PEARSON (on camera): The jobs report is coming one day early because of the 4th of July holiday, will there be fireworks? We`ll have to wait for the numbers to find out.

For NIGHTLY BUSINESS REPORT, I`m Hampton Pearson in Washington.


GRIFFETH: It is all about jobs. We had more evidence of more small businesses taking on more new hires in the month of June. The National Federation of Independent Business says that hiring increased in June for the ninth consecutive month. That`s the longest stretch of increases that we have seen since 2006. More than half of the small businesses` owners surveyed by those groups either made at least new hires or posted job
openings over the last three months.

GHARIB: Turning now to Wall Street. It was a lazy summer day of trading, but there was still enough oomph for the Dow and S&P 500 to hit new records, and the advances came despite disappointing economic news showing that factory orders in May rose much less than expected.

Here`s how the major averages look at the closing bell. The Dow rose
20 points, the NASDAQ lost a fraction, and the S&P inched up by a point.

Even with the Dow and the S&P standing at historic highs, Dominic Chu reports that investors are still finding value in the stock market.


Finding value in a stock market that sits at record highs can be tough, but it`s not impossible. Investing philosophy and strategy are important.
Oftentimes, it means looking for a few key characteristics to help find the
right stocks.

MICHAEL FARR, FARR, MILLER & WASHINGTON PRESIDENT: Most important of anything I look for is earning`s growth, consistent earning`s growth historically and prospectively. I have to know how a company is making money and how it`s going to continue to make money and expand those

CHU: That might be one of the reasons why investors have found favor in shares of computer chip maker Intel (NASDAQ:INTC). It`s one of the leading performers in the Dow Jones Industrial Average this year and has grown earnings per share by around 15 percent per year over the last five years. But while many companies are showing signs of strength, picking when to get into the stock market can be tricky.

Some experts are still waiting for the right time.

MAURY FERTIG, RELATIVE VALUE-PARTNERS CEO: You had 23 record highs in the S&P 500 in 2014. Don`t let that sweep you up and shift to get more aggressive at this point in time. So, I think diversification is the key across both asset classes and geographically going into the end of the

CHU: And that brings us to another key point. Investors don`t have to be limited to just investing here in the U.S. Depressed prices
elsewhere around the world could provide intriguing opportunities.

DARIN RICHARDS, AKT WEALTH ADVISORS LLC: Right now we`re about 2/3 domestic, 1/3 international and we`ll switch to 50/50. We like what we see in Europe. It`s certainly slower growth than what you see in the United States. But I feel like it`s kind of the early stages of a recovery, and
it hasn`t taken hold yet. But often times, that`s the best time to invest.

CHU: In the end, many experts believe that taking a diversified approach to investing could be the right way to go.



GRIFFETH: Investors today had their first chance to react to news that JPMorgan (NYSE:JPM) Chase chairman and CEO, Jamie Dimon is suffering from throat cancer. Now, despite the company unveiling short, medium and long-term succession plans, investors did sell some of the stock today. It ended 1 percent lower, making it the worst-performing Dow component. The 58-year-old Mr. Dimon says the cancer was caught at an early stage. It is treatable and curable through radiation and chemotherapy and he plans to
stay on the job.

GHARIB: Fees at JPMorgan (NYSE:JPM) and other global investment banks total $47 billion in the first six months of the year, that`s the most since 2007. The 12 percent jump in fees from 2013 coincided with the surging stock market, which encouraged many firms to strike more deals, according to Thomson Reuters (NYSE:TRI). The gains were highest in Europe, up 29 percent. That compares to just 6 percent in the Americas.

GRIFFETH: A big change in Fidelity Investments in the wake of stricter regulatory oversight out of Washington. The financial services firm is now telling U.S. clients who live outside the country they can no
longer buy or trade mutual funds in the brokerage accounts.

GHARIB: PIMCO, the world`s biggest bond fund manager, could use some oversight in its total return fund. It posted its 14th straight month net flows in the month of June, with another $4.5 billion in withdrawals.

But PIMCO founder Bill Gross says there is nothing to worry about.


BILL GROSS, PIMCO CO-FOUNDER & CIO: The tide comes in, the tide goes out. We think it comes in again. It`s based on performance. The total return fund in the last several months is in the 85th percentile. For the year, we`ve returned close to 4 percent for bond investor. You know, the tide is going to come back in again, and the total return fund will remain
the number one bond fund in the world.


GHARIB: In a statement, a PIMCO spokesman said the total return fund has outperformed its benchmark in many peers over the last 15 years.

GRIFFETH: Still ahead, if you buy prescription drugs either online or at a discounter and not through traditional pharmacies, will those drugs be safe? We have the results of a six-month investigation, coming up.


GHARIB: Americans seem to have a love-hate relationship with the big fast food chains. A new survey from “Consumer Report” says all of the signature meals as the big chains are the worst in their categories. So, take for example, McDonalds, it has the worst burgers out of 21 in national and regional chains. KFC makes the worst chicken, out of eight chains in the survey. Taco bell sells the worst burritos out of eight Mexican fast food sellers.

But some other national names came out on top. Chick-fil-A has the best chicken, and Chipotle, the best burritos

GRIFFETH: Well, Facebook (NASDAQ:FB) maybe tops in serving up humble pie right now. The social networking giant is apologizing for conducting a psychological experiment on 700,000 unsuspecting users. They tried to manipulate members` emotions by sending posts to their news feeds with either positive or negative slants to see if they would respond accordingly.

Facebook`s chief operating officer Sheryl Sandberg apologized on behalf of the company, saying the purpose of the experiment was, in her words, poorly communicated.

GHARIB: Target (NYSE:TGT) is asking customers not to bring their guns into stores, even where permitted by law. The retailer says it listened to both sides of the debate and decided that banning firearms from its stores would create a safer environment for shoppers and employees.

GRIFFETH: We begin tonight`s “Market Focus” with a disappointing revenue report from Delta.

The airline saw its revenues rise but less than in previously forecast. It cited lower than expected international yields and lower business demand to Latin America because of the World Cup. That sent shares down by 5 percent, closed at $38.24, and other airlines fell in sympathy.

Investors cheered Constellation Brands (NYSE:STZ) as that company posted an earnings beat. The results were also helped by its acquisition of beer maker Grupo Modelo. It also upped its full-year outlook. The CEO says it wasn`t just Constellation`s beer unit, though, that`s been performing well.


ROB SANDS, CONSTELLATION BRANDS CEO: We`ve been firing on all cylinders as a company. Our beer business is incredibly strong. Our wine business is strong. Our spirits business is strong. We had a great
quarter. We exceeded expectations.


GRIFFETH: Constellation Brands (NYSE:STZ) up more than 2 percent today to $90.45.

Boeing (NYSE:BA) signed a nearly $3 billion contract with NASA to develop the core stage of the Space Launch System, which is set to be the most powerful rocket ever built and it may one day take astronauts to Mars.
Despite that news, though, shares of Boeing (NYSE:BA) fell a fraction to $127.62.

GHARIB: Shares of Greenbrier popped on its earnings report. The railroad car maker upped it full-year forecast after it announced better than expected quarterly results — thanks to an increase in deliveries.
The stock jumped almost 12 percent to $64.61.

Shutterfly (NASDAQ:SFLY) shares soared on speculation the online photo-sharing service is putting itself up more sale. Reportedly, the company is working with a boutique investment bank Qatalyst Partners, but the discussions are at an early stage. The stock still jumped 15 percent to $50 a share.

And Rackspace is taking a different path. This Cloud service provider is reportedly considering taking itself private and it`s in talks with a private equity firm to fund the deal. The option to go private is said to have come amid three acquisition bids for the company. Shares rose more than 6 percent to $35.88.

GRIFFETH: Well, the high cost of prescription drugs here in the U.S.
has caused some surprising and potentially risky side effects with more Americans buying their drugs outside our borders. Is it worth the risk to play a kind of prescription roulette?

Scott Cohn is with us now with more on this troubling story — Scott.

SCOTT COHN, NIGHTLY BUSINESS REPORT CORRESPONDENT: And it`s not a clear cut case, Bill. The drug company says part of what you`re paying for with the high prices is safety, which doesn`t explain the low prices in other parts of the world. The alternative sellers claim they can get you safety, too, but at a much lower cost.

So, is it cost versus risk? Here`s what we found.


UNIDENTIFIED FEMALE: You are wrong. Totally wrong.

COHN (voice-over): We`re not wrong. The prescription Lipitor we purchased under cover from this business in Florida and had tested is different from the Lipitor we got from a traditional pharmacy.

UNIDENTIFIED MALE: Hi. We need to get this filled.

COHN: But like just everything else involving prescription drugs, this story is a lot more complicated than that. We had gone undercover to look at the explosion of what are known as facilitators, basically brick and mortar versions of Internet pharmacies offering prescription drugs at big discounts. They claim to be legal. But drug companies say they`re exploiting a legal loophole.

(on camera): We found these businesses all over the place here in Florida where a lot of seniors are on expensive prescription drugs but might not feel comfortable ordering them online. So the idea, I can take a prescription like this, they will fill it, they`ll ship it to my house at a huge savings.

(voice-over): Discounts as much as 80 percent or so they claim. Some
people like this woman who wouldn`t give her name swear by these places.

UNIDENTIFIED FEMALE: People need to save money and drug prices are
too high. It`s simply economic.

COHN: But the National Association of Boards of Pharmacy says ordering from a facilitator carries the same risks as ordering from a Web
site and those risks, they say, are considerable.

CARMEN CATIZONE, NABP EXECUTIVE-DIRECTOR: Now, of more than 10,000 sites that we looked at, 97 percent of those sites are illegal or rogue
sites and they`re operating dangerously.

COHN: Often selling counterfeit drugs, which is where this lab in Groton, Connecticut, comes in. It`s run by Pfizer (NYSE:PFE) and we got
rare access. Here they can test a pill.


COHN: With pretty much the push of a button.

UNIDENTIFIED FEMALE: This fails. This is a counterfeit tablet that
we ran.

COHN: Pfizer (NYSE:PFE) director of global security Brian Donnelly is
a former FBI agent and a pharmacist.

BRIAN DONNELLY, PFIZER GLOBAL SECURITY DIRECTOR: The big motivation here is patient safety. We want to make sure that when a patient gets a Pfizer (NYSE:PFE) medication, that they get a Pfizer (NYSE:PFE) medication.
Not some knock off.

COHN: Some of what they are finding online is frightening.

DONNELLY: They`ll use things like brick dust to hold it together.
They will use wallboard, sheet rock to hold these things together because
they compress well.

COHN: To see if the facilitators are any different from the online sellers, Pfizer (NYSE:PFE) agreed to help us put them to the test. We ordered brand-name Lipitor at four locations in Florida, and we filled two more at traditional pharmacies in New York and New Jersey.

UNIDENTIFIED MALE: I need to get this prescription filled. I don`t
know if you — I need the brand name, though. I`m not sure if you have it.

COHN: The first difference is obvious, the price. The facilitators charged us on average $1.71 per pill. The pharmacies more than four times


COHN: But when we got our shipments, there was another difference.
The pills from the pharmacies are oblong, but look at the pills from facilitators, they`re round. We sent simples of each to Pfizer`s lab, removing all the packaging to keep the test blind.

Think you know how the test came back? Think again.

(on camera): According to Pfizer`s report, the oblong Lipitor from the traditional pharmacies came back authentic, no surprise.

But what about the round Lipitor that came in the mail? It turns out, according to Pfizer`s own analysis, it`s authentic, too.

(voice-over): Authentic Pfizer (NYSE:PFE) manufactured drug product the report says but not intended for distribution in the U.S. That`s right, Pfizer (NYSE:PFE) makes two kinds of Lipitor, the drug sold in the U.S. and the drug sold overseas, at a fraction of the price.

(on camera): I think a lot of people would be surprised that Pfizer
(NYSE:PFE) makes more than one kind of Lipitor.

DONNELLY: We make products around the world.

COHN (voice-over): Pfizer`s Brian Donnelly says the overseas Lipitor
is the same drug and the same quality.

DONNELLY: Whatever product Pfizer (NYSE:PFE) makes is going to be a
top shelf product.

COHN (on camera): So what`s the risk to a patient beyond saving a lot of money of ordering this way?

DONNELLY: The risk is any time you go outside of the U.S. system,
you`re circumventing a system put in place for your safety.

COHN (voice-over): He says the higher price in the U.S. buys you the FDA and what he calls a closed system to keep out substandard or counterfeit drugs. It happens to also keep out the less expensive overseas Lipitor.

And June Boti (ph) at Canada discount RX Services says that`s what is
really going on here.

UNIDENTIFIED FEMALE: We saved a lot of money for elderly people. I
have a lot of happy customer.


COHN: An attorney for two of the other facilitators we`ve visited said they do try to make sure that they order from overseas pharmacies that follow similar standards to those required by the FDA. The owner of the fourth business says he requires all his suppliers to be licensed in their home country.

Pfizer (NYSE:PFE) meanwhile points out it spent more than $7 billion in the last five years to help people afford prescriptions through an
assistance program called RX Pathways.

GRIFFETH: Fascinating. So if somebody decides they want to buy prescription drugs online, are there steps they can take to make sure to get the real thing?

COHN: Well, they need to make certain, first of all, that they know they are taking a calculated risk. But there are legitimate Internet pharmacies. The International Board of Pharmacies does a check on this and
on their Web site you can check out these Internet pharmacies.

GHARIB: All right. So, Scott, I`m going to put you on the spot. You worked on this for six months. You know everything about this now. Would you ever buy these off market drugs because they are cheaper? Are you tempted?

COHN: Well, I think that anybody that`s looking at the high price and wants to take their medication but can`t afford it has got to look at this and look at the results that we found, but it`s still a calculated risk.
As Pfizer (NYSE:PFE) points out, as the NABP points out, they may send you good product one time and not the next. So, if you don`t check them out,
you`re taking a risk.

GHARIB: Fascinating story.

GRIFFETH: Great stuff.

GHARIB: Thank you so much, Scott Cohn.

And to read more about Scott`s investigation, log on to our Web site,

And coming up on the program, it`s Nike (NYSE:NKE) versus Adidas.
You`ve no doubt seen the brands during the World Cup. Tonight, we`ll see which is scoring on the global business stage in NBR`s ultimate stock cup.
That`s next.


GHARIB: No matches today in the World Cup soccer tournament in Brazil, but the quarterfinal round begins on Friday without the U.S. after that heartbreaking loss to Belgium.

But in the latest round of NBR`s ultimate stock cup, two sneaker and athletic wear giants square off in the global marketplace, the U.S.`s Nike
(NYSE:NKE) versus Germany`s Adidas.


GHARIB (voice-over): The swoosh is a global icon and Nike (NYSE:NKE) is the largest sportswear company in the world. It was founded in 1964 as Blue Ribbon Sports by Phil Knight and his former track coach Bill Bowerman.
It`s headquartered near Beaverton, Oregon. 2013 revenue: more than $25 billion.

They formed Blue Ribbon when Knight brought home running shoes from Japan. In 1971 the company took the name Nike (NYSE:NKE), the Greek goddess of victory. It soon expanded to apparel and equipment, and Michael Jordan still tops a Hall of Fame list of athletes that helps Nike
(NYSE:NKE) change the footwear and fashion industry.

At this year`s World Cup, Nike (NYSE:NKE) outfitted 10 teams, one more than Adidas, but Adidas makes the official World Cup soccer ball.

Founded in 1948, Adidas is headquartered in Bavaria, Germany. 2013 revenues just under $20 billion.

The founder, Adolf Adi Dassler, had been making athletic shoes since the 1920s. Adidas is also a game changer. It was one of the first companies to pay athletes and teams using its gear. The Adidas logo, three parallel bars became known around the world long before there ever was a


GRIFFETH: So which sneaker and athletic apparel giant is the winner in this global rivalry? Is it Nike (NYSE:NKE) or Adidas?

Let`s ask Burt Flickinger. He joins us, managing director with the Strategic Resource Insight Group.

You made an interesting comment, you think Adidas makes a better product but you vote Nike (NYSE:NKE), why?

Because Phil Knight, since he co-founded Nike (NYSE:NKE), is like the Julius Caesar of sports, he conquers everything in sight and this year, the last frontier to win is football or soccer and Nike (NYSE:NKE) will eclipse Adidas` last salient strength and beat Adidas in worldwide soccer and
football sales this year.

GHARIB: So, what are you saying? That Nike (NYSE:NKE) is a more innovative brand?

FLICKINGER: Nike (NYSE:NKE) can be — Nike (NYSE:NKE) is innovative.
Adidas — are both innovative. Nike (NYSE:NKE) can be mass manufactured at better prices. Adidas may be better quality, but Nike (NYSE:NKE) has
better teams, better athletes, better sales, better growth, better margin.

GRIFFETH: It`s that intangible thing we call brand. I mean, that`s
what attracts a lot of people.

GHARIB: The cool factor.

GRIFFETH: The coolness factor, right. Right?

FLICKINGER: The cool factor, whether it`s athletics, whether it`s music, whether it`s popular culture, Nike (NYSE:NKE) wins on all fronts.
Every major continent, every country, every consumer constituency

GHARIB: Let`s talk about China because I guess Nike (NYSE:NKE) has a stronghold but Adidas is moving in. So, it`s sort of a neck and neck rivalry there. Who wins there?

FLICKINGER: Ultimately, Nike (NYSE:NKE) will win because Nike
(NYSE:NKE) will sponsor the Chinese ping-pong team, the football team, the basketball team, the key athletes, and ultimately, that`s what that catches
on in what`s cool with the kids.

GRIFFETH: Would we get the same answers in Europe? They wear Adidas quite a bit other there, don`t they?

FLICKINGER: The Adidas three stripe to your point, Bill, is very popular, particularly in its home country of Germany. But Adidas has been around for 90 years and one for several decades. Nike (NYSE:NKE) since Caroline Davidson developed the swoosh and was patented in `74, Nike
(NYSE:NKE) has have been coming on strong, better advertising better marketing with Wieden Kennedy and Nike (NYSE:NKE) wins on all fronts
worldwide. But in Europe, that is the stronghold.


GHARIB: So, what happens when Nike (NYSE:NKE) see a chairman and founder Phil Knight steps off the field, so to speak? I mean, that point is going to come. Will you feel the same way about Nike (NYSE:NKE) and its innovation? It sort of reminds me a lot of the Steve Jobs Apple
(NASDAQ:AAPL) connection.

FLICKINGER: It`s an important consideration, particularly relating to Steve Jobs, because both were such inspirational leaders, great innovators, great entrepreneurs.

Phil Knight`s built a powerful brand machine as you referenced, Bill, but also a war machine to take down every competitor in every sport, every category. So, that machine will continue for at least a decade after Phil
Knight steps aside and in the `70s, he`s still going strong.

GRIFFETH: Yes, he is.

So, how do you view both as investments? Do you —

FLICKINGER: Investments, because of higher double digit growth at Nike (NYSE:NKE) and increasing margins, Nike (NYSE:NKE) will be the ultimate winner. So, while Adidas stock is trading in the ADR (ph) is at
$100 today, Nike (NYSE:NKE) is trading at about $76. By the time the next World Cup comes around, both will be up but Nike (NYSE:NKE) will be up significantly over Adidas.

So, for short term/long term, Nike (NYSE:NKE) is a better investment.

GRIFFETH: Burt, good to see you. Good to see you tonight.


FLICKINGER: Thank you.

GRIFFETH: Burt Flickinger of the Strategic Resource Insight Group.

So, you just heard what Burt said. We want to hear from you on this
one: which stock do you prefer, Nike (NYSE:NKE) or Adidas? Go to our Web site and vote at

GHARIB: And don`t go away. Now, the results from last night`s global rivals challenge where we ask you to choose between General Motors
(NYSE:GM) and Toyota (NYSE:TM). The winner: Toyota (NYSE:TM), 77 percent
of you voted for the Japanese automaker.

GRIFFETH: Finally tonight, did you use up a lot of vacation days this year? Have you yet? Chances are no. Nearly half of us didn`t use all of our vacation days.

There is a new study from Oxford Economics that says hard working Americans leave an average of eight vacation days unused per year. That`s a staggering total of 429 million unused vacation days each year. That`s more than a million years worth. Just think about that and more than any
other workforce on Earth. We just don`t like to go on vacation.

GHARIB: We`re workaholic. We`re hard working Americans, Bill.

GRIFFETH: I`d say we take tomorrow off, but no, let`s come back tomorrow, too. Shall we?

GHARIB: Can`t we?

GRIFFETH: Exactly.

GHARIB: That`s NIGHTLY BUSINESS REPORT for tonight. I`m Susie
Gharib. Thanks so much for watching.

GRIFFETH: I`m Bill Griffeth. Have a great evening. We will see you tomorrow.


Nightly Business Report transcripts and video are available on-line post broadcast at The program is transcribed by CQRC Transcriptions, LLC. Updates may be posted at a later date. The views of our guests and commentators are their own and do not necessarily represent the views of Nightly Business Report, or CNBC, Inc. Information presented on Nightly Business Report is not and should not be considered as investment advice. (c) 2014 CNBC, Inc.

This entry was posted in Transcripts. Bookmark the permalink.

Leave a Reply